The research team led by Associate Professor Wen-Wei Lin at Kaohsiung Medical University has successfully developed a novel Dual-State Chromogenic Enzyme (DSCE) reporter gene system. This innovative system, which combines membrane-bound and secreted chromogenic enzymes, provides a highly sensitive, stable, and cost-effective solution for high-throughput drug screening. By significantly enhancing the speed and accuracy of drug screening, the DSCE system offers a more efficient and economical approach to drug discovery.

Addressing Drug Screening Challenges and Improving Efficiency

Drug or compound screening plays a pivotal role in biotechnology and pharmaceutical development. However, traditional dual luciferase assays face multiple limitations, such as high costs of chemical substrates, cumbersome procedures, insufficient signal stability, and the need for specialized equipment. These factors hinder the efficiency and cost-effectiveness of high-throughput drug screening.

Mechanism and Advantages of the DSCE System

The DSCE system uses genetic engineering techniques to present chromogenic enzymes in two forms: on the cell membrane (MTCE) and secreted into the extracellular space (SCE). This dual-state structure assigns one enzyme as the reporter gene and the other as the internal control, ensuring experimental stability. The system boasts five key advantages:

Low-cost, stable substrates: Significantly reduces experimental costs.

Direct substrate interaction: Minimizes data variability.

Long enzyme half-life: With a half-life of 14 to 18 hours, it is suitable for long-duration experiments.

High signal stability: Ideal for large-scale screening.

Compatibility with standard ELISA readers: Reduces equipment requirements.

Empirical results demonstrate that the DSCE system's sensitivity under various promoters is comparable to, if not better than, traditional luciferase assays. Its chromogenic signal stability is markedly superior. Cost analysis reveals that the DSCE system reduces costs by approximately 30-fold and increases operational efficiency by 3.2 times, saving users an estimated $270,000 annually in labor and material expenses. This confirms the system’s ability to deliver stable and reliable results for long-term, large-scale operations.

Future Prospects: Transforming the Market with Innovative Technology

Through advanced genetic engineering, Associate Professor Lin’s team has overcome several bottlenecks associated with traditional dual luciferase assays. The DSCE system not only reduces costs and enhances screening efficiency but also simplifies the drug development process. Currently, the technology has entered the pilot production stage, with plans to promote it in the market via technology transfer, collaborative development, or direct sales.

Looking ahead, the team plans to expand the application of the DSCE system to clinical diagnostics by developing specialized diagnostic reagent kits for various diseases. This will enable deeper integration of medical and industrial applications, driving innovation in both healthcare and the pharmaceutical industry.

Resource: 基因工程介入 新雙型態呈色酵素技術簡化藥物開發